Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Irisity in conjunction with the acquisition of Agent Vi and a directed share issue
Mandate

Vinge advises Irisity in conjunction with the acquisition of Agent Vi and a directed share issue

September 03, 2021 M&A Capital Markets and Public M&A EU, Competition and Regulatory

Vinge has advised Irisity AB (publ) in connection with its acquisition of all shares in the Israeli company Agent Video Intelligence Ltd for a purchase price of approximately SEK 580 million.

The purchase price shall be paid in cash, and in part by way of newly issued shares in Irisity. Closing is subject to a resolution adopted at Irisity’s extraordinary general meeting to authorise the board of directors to adopt a resolution concerning a non-cash issue.

In connection with the closing of the transaction, Vinge advised Irisity regarding a directed share issue that was performed as an accelerated bookbuilding arranged by Erik Penser Bank at a subscription price of SEK 49. Irisity received SEK 130 million before issue costs.

Vinge’s team consisted of Anders Strid, Anna Ståhlklo (M&A), Edin Agic (ECM) and Adrian Filipovic (ECM). S. Horowitx&Co acted as legal counsel in Israel in connection with the acquisition.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024